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Abstract
The evolution of drug resistance in HIV occurs by the fixation of specific, well-known, drug-resistance mutations, but the
underlying population genetic processes are not well understood. By analyzing within-patient longitudinal sequence data,
we make four observations that shed a light on the underlying processes and allow us to infer the short-term effective
population size of the viral population in a patient. Our first observation is that the evolution of drug resistance usually
occurs by the fixation of one drug-resistance mutation at a time, as opposed to several changes simultaneously. Second, we
find that these fixation events are accompanied by a reduction in genetic diversity in the region surrounding the fixed drug-
resistance mutation, due to the hitchhiking effect. Third, we observe that the fixation of drug-resistance mutations involves
both hard and soft selective sweeps. In a hard sweep, a resistance mutation arises in a single viral particle and drives all
linked mutations with it when it spreads in the viral population, which dramatically reduces genetic diversity. On the other
hand, in a soft sweep, a resistance mutation occurs multiple times on different genetic backgrounds, and the reduction of
diversity is weak. Using the frequency of occurrence of hard and soft sweeps we estimate the effective population size of
HIV to be 1:5|105 (95% confidence interval ½0:8|105,4:8|105 ). This number is much lower than the actual number of
infected cells, but much larger than previous population size estimates based on synonymous diversity. We propose several
explanations for the observed discrepancies. Finally, our fourth observation is that genetic diversity at non-synonymous
sites recovers to its pre-fixation value within 18 months, whereas diversity at synonymous sites remains depressed after this
time period. These results improve our understanding of HIV evolution and have potential implications for treatment
strategies.
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Introduction
Understanding the process of adaptation is one of the basic
questions in evolutionary biology. The evolution of drug resistance
in pathogens such as HIV is a prime example of adaptation and a
major clinical and public health concern because it leads to treat-
ment failures.
The likelihood that a population adapts in response to an
environmental challenge, e.g., a viral population in a patient
develops resistance in response to a drug treatment, depends,
among other things, on the amount of genetic diversity that the
population harbors [1,2]. The amount of genetic diversity in a
population depends in turn on the details of the adaptive process.
In the classical model of adaptation, a beneficial mutation arises
once in a single individual and, as this mutation increases in
frequency in the population, other mutations ‘‘hitchhike’’ with it to
high frequency [3]. In this process, referred to as a ‘‘hard selective
sweep’’, genetic diversity at linked sites is strongly reduced when
the beneficial mutation fixes in the population. However, if the
population is sufficiently large, beneficial mutations will occur
frequently or will be present in multiple copies prior to the onset of
selection. Then, multiple beneficial alleles may replace the wild-
type without leading to a significant reduction in diversity. This is
called a ‘‘soft selective sweep’’ [4].
We use HIV as a model system to ask the following evolutionary
questions. How much do selective sweeps affect genetic diversity at
neighboring sites? How often does adaptation occur via soft and
hard sweeps? What is the effective population size of HIV relevant
for adaptation (later referred to simply as Ne)? How does diversity
recover after a selective sweep at synonymous and non-synony-
mous sites? Three factors make HIV well suited to address these
questions: (a) HIV evolves rapidly due to its short replication time
and high mutation rate, (b) HIV populations in different patients
act as independent replicates of the same evolutionary process, and
(c) the main genetic targets of positive selection in HIV during
antiviral treatment are known: these targets are drug-resistance
mutations which have been well characterized.
From the questions above, the estimation of the short-term effec-
tive population size (Ne) of HIV is perhaps the most interesting and
clinically important. We are interested in the short-term effective
population size because it is one of the determinants of the prob-
ability that drug resistance evolves in a certain generation. This
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processes (such as possibly background selection), and much less
so by historical processes or events (such as bottlenecks). The
question of the effective population size of HIV has been a subject
of a heated debate because of enormous discrepancies in the
estimates obtained by different methods (see [5] for a review). In an
influential 1997 paper, Leigh-Brown used genetic diversity at
synonymous sites and estimated the effective size of the viral
population to be on the order of 103 [6]. Around the same time, it
became clear that the number of active virus-producing cells in the
body of an infected person was around 108 [7] which lead to a
natural expectation that the viral population should be very large
with almost deterministic evolutionary dynamics [8]. However,
Frost et al found that frequencies of resistance mutations before the
start of treatment varied greatly between patients, which led them
to conclude that stochastic effects play an important role in HIV,
and the population size must therefore be 106 or smaller [9]. With
more data and a more sophisticated linkage disequilibrium-based
method Rouzine and Coffin inferred that the population size of the
virus must be at least 105 [10]. Finally, a recent study by Maldarelli
et al [11] places Ne between 103 and 105, based on changes in allele
frequencies over time.
We estimate Ne of HIV using previously published longitudinal
sequence data from several HIV-infected patients under drug
treatment [12]. Our approach to estimating Ne is most closely
related to the recent estimates done in Drosophila [13], Plasmodium
[14], and a chimeric simian-human immunodeficiency virus [15],
but differs from these studies in that we use data from several
patients for increased statistical power. The main idea of our
method is as follows. Since the mode of adaptation (hard versus
soft sweeps) depends on the supply of beneficial mutations which
in turn depends on the effective size of the population, it is possible
to use the observed frequency of hard and soft sweeps to estimate
Ne. The key problem is to distinguish hard and soft sweeps in the
sequence data. We address this problem by taking advantage of a
unique property of codon 103 in the reverse-transcriptase gene,
namely that there are two distinct nucleotide changes that convert
the (wildtype) amino acid lysine into asparagine, which confers
drug resistance. If both of these nucleotide changes are observed in
a single sample, a soft sweep must have occurred.
While the effects of selection and demographic processes on the
reduction of diversity have been extensively studied, the question
of how diversity recovers after perturbations has received little
attention. Yet, understanding the dynamics of recovery is
important because it determines how long signatures of selective
sweep or bottlenecks remain detectable in genetic data. Failure to
account for the time it takes for diversity to reach its equilibrium
after a perturbation can lead to biases in estimation of population
genetic parameters such as Ne [5]. Using longitudinal data we
show here that diversity after a selective sweep recovers faster at
non-synonymous sites than at synonymous sites.
Results and Discussion
Selective sweeps reduce genetic diversity
We study how the genetic composition of HIV populations in
patients treated with a combination of reverse transcriptase (RT)
and protease inhibitors changed over the course of about one year
(see Ref. [12] and Loss of diversity for details on the data). Out
of 118 patients studied in Ref. [12], we selected a subset of 30
patients in which the virus had no resistance mutations at the start
of the study but fixed a resistance mutation at one of the later time
points. All our analyses were done on this subset of patients (see
Loss of diversity for details). We note that in 24 out of 30
patients (80%) we detect fixation of a single resistance mutation
within the observation period, even though all patients were
treated with multiple drugs (see Suppl Table S1).
Samples taken prior to treatment in these patients show
nucleotide diversities of *3% at synonymous sites and v1% at
non-synonymous sites. At the time points when we detect fixations
of drug-resistance alleles at one or several known sites we observe a
substantial decrease in the levels of polymorphism in the 1 Kb
region that was sequenced (see Figures 1, 2, 3, and Loss of
diversity). Between the last sample before and the first sample
after the fixation of the first drug-resistance mutation, viral popu-
lations lose 53% of their genetic diversity, measured by the median
drop in per-site heterozygosity. This difference is significant, with
Pv10{3 (all P-values we report are from Mann-Whitney tests).
We observe no loss of diversity in control intervals in which no
resistance mutation was fixed (see Loss of diversity).
The loss of diversity that we observe is a result of hitchhiking:
when an adaptive mutation rapidly increases in frequency, it takes
with it the genetic background on which it arose [3]. Three factors
can attenuate the observed loss of diversity after a sweep. First,
recombination can preserve some diversity by allowing sites at
some distance from the selected site to escape the effects of the
sweep [16]. Recombinational escape does not appear to be a
factor in these data however because we do not observe a corre-
lation between post-sweep heterozygosity and distance from the
selected site (see Recombination). This is consistent with previ-
ously reported observations in HIV [17].
Second, the amount of diversity lost depends on the origin of the
adaptive allele. Diversity may survive the fixation of an adaptive
allele even in the absence of recombination if the selective sweep is
‘‘soft’’, i.e., if the same adaptive allele arises via multiple mutations
on different genetic backgrounds [18]. On the other hand, genetic
diversity at neighboring sites is reduced dramatically if the selective
sweep is ‘‘hard’’, i.e., if the adaptive allele originates through a
single mutation on one genetic background [3]. We demonstrate
below that both soft and hard sweeps occurred in these patients.
Importantly, whether soft or hard sweeps predominate in a popula-
tiondepends onthe supplyof adaptive mutations whichis determined
Author Summary
It is well known that HIV can evolve to become drug
resistant if it acquires specific drug-resistance mutations,
but the underlying population genetic processes are not
well understood. We found that the evolution of drug
resistance in HIV populations within infected patients
occurs by one mutation at a time (as opposed to multiple
mutations simultaneously) and involves both hard and soft
sweeps. In a hard sweep, a mutation originates in a single
viral particle and then spreads to the entire viral
population within the patient. As this mutation increases
in frequency, other mutations linked to it hitchhike to high
frequencies, which greatly reduces genetic diversity in the
population. In a soft sweep, on the other hand, the same
resistance mutation originates multiple times on different
genetic backgrounds, and hitchhiking may have very little
or no effect on diversity. The fact that drug resistance
evolves by means of both hard and soft sweeps implies
that the HIV populations are limited by the supply of
resistance mutations. Using the frequency of hard and soft
sweeps we obtain a point estimate of 150,000 for the
effective population size of the virus, a number that is
much higher than estimates based on diversity at neutral
(synonymous) sites, but much lower than the actual
number of HIV infected cells in a human patient.
Selective Sweeps in HIV
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effective population size. If adaptive mutations appear in the
population on average more than once per viral generation, they
are likely to fix via soft sweeps. If adaptive mutations appear on
average less than once per generation, they typically fix via hard
sweeps [4]. Thus, we can assess the supply rate of resistance
mutations by determining whether the observed selective sweeps
are soft or hard.
Third, the observed loss of diversity depends on whether new
mutations occur between the fixation of a resistance allele and the
time when samples are taken and the sweep is observed. Since we
do not know the actual time of fixation, we do not know the
absolute amount of diversity loss due to the sweep. However, this
fact does not obscure informative patterns of relative loss of
diversity, for synonymous versus non-synonymous mutations and
for soft versus hard sweeps.
Estimating Ne from the frequency of soft sweeps
In 17 of the 30 HIV populations (57%), we observe the fixation
of just one, well-known drug resistance mutation, K103N (lysine to
asparagine) in RT. This mutation confers high-level resistance to
the non-nucleoside RT inhibitor used by the patients [12]. Two
different nucleotide changes produce the same K103N amino acid
change. The wildtype codon AAA encoding lysine can mutate to
either codon AAC or codon AAT both encoding asparagine which
confers resistance. This property is unique to the K103N mutation
among all resistance mutations observed in these patients (see
Suppl. Table S1) and can be used to distinguish soft and poten-
tially hard sweeps.
In 7 of these 17 populations (41%) both codons (AAC and AAT)
that code for asparagine are present in the population in the first
sample after the sweep (Figure 1). These are certain to be soft
sweeps. As expected, the median reduction of diversity in these
populations is only 15% and not significantly different from 0. In
the remaining 10 patients (59%) only one codon is present after the
sweep (AAC in 6 and AAT in 4 patients; Figure 2). These sweeps
could be either soft or hard. If in these 10 ‘‘one-codon’’ patients
the resistance allele typically arose via the same number of unique
mutation events as in the 7 ‘‘two-codon’’ patients, we would expect
to see a similarly small reduction in diversity at linked sites in these
Figure 1. Soft sweep in patient 058. Codon AAA coding for lysine at position 103 was replaced by day 28 with a mixture of codons AAT and AAC
both coding for asparagine which confers resistance to NNRTI drugs. Genetic diversity close to the selected site was not significantly reduced. The
plot shows only the polymorphic sites among the first 500 basepairs of the reverse transcriptase region. Each row represents a sequenced viral
isolate. Each column represents a polymorphic site, with the derived synonymous and non-synonymous polymorphisms shown in black and orange
respectively. Codon 103 is shown explicitly. It is grey when coding for lysine (susceptible) and blue when coding for asparagine (resistant). The
responsible mutations are colored pink (T) and yellow (C).
doi:10.1371/journal.pgen.1004000.g001
Selective Sweeps in HIV
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viral populations, genetic diversity is reduced by 71% (P~0:003),
and the difference between the ‘‘two-codon’’ and ‘‘one-codon’’
populations is significant (P~0:007). It is possible that two codons
initiallyfixed in the ‘‘one-codon’’ patientsbutone of the codonswas
lost (for example, due to another sweep) before the sample was
taken. This scenario would have been plausible if the time intervals
between samples were, for some reason, longer in the ‘‘one-codon’’
than in the ‘‘two-codon’’ patients. However, we observe no statis-
tical difference in the inter-sample time intervals between the ‘‘two-
codon’’ and ‘‘one-codon’’ patients (P~0:48). Wethereforeconclude
thattheselectivesweepsinthe‘‘one-codon’’patientsareduetofewer
mutational origins than in the ‘‘two-codon’’ patients, and some are
likely hard sweeps (see Figure 2).
The fact that we observe both soft and hard sweeps implies that
the K103N mutation appears roughly once per generation [4]. A
more accurate estimate of the mutation supply rate h=2 based on
the frequencies of AAC and AAT alleles in the post-sweep samples
yields h=2~0:3 new K103N mutations per generation (95%
confidence interval ½0:17,0:97 ). Assuming that we sample 6 viral
isolates per patient (which is the median in our dataset), theory
predicts that, if h=2~0:3, 30% of populations would show a hard
sweep signature (i.e., the sweep would be due to a single origin),
which is consistent with our observations. Assuming the point
mutation rate of 2|10{6 per generation for transversions [19],
we estimate the effective population size of HIV populations to be
Ne~1:5|105 ½0:8|105,4:8|105  (see Estimating the supply
rate of resistance mutations for details).
We estimated Ne based on data from the 17 patients in which
the K103N mutation fixed. Although we cannot do the same
analysis with the other resistance mutations in the dataset, we find
that the median reduction in diversity in the other 13 patients is
intermediate between the ‘‘one-codon’’ and ‘‘two-codon’’ K103N
patients (see Suppl. Figure S1), which suggests that K103N
mutation is not special and that similar processes are taking place
at the other resistance sites. Further, the haplotype structures in
two patients with amino-acid changes in the 190th codon position
suggest a soft sweep in one and a hard sweep in the other (see
Suppl. Figure S2). Thus adaptation at the 103rd codon position
appears to be representative of adaptation at other codon positions.
There are other amino acid changes that are similar to the
lysine to asparagine (K to N) change in that they can be achieved
Figure 2. Putatively hard sweep in patient 086. Codon AAA coding at position 103 was replaced by day 84 with codon AAT. Genetic diversity
around the selected site was strongly reduced. Notations as in Figure 1.
doi:10.1371/journal.pgen.1004000.g002
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amino acid changes (limited to those changes that are one muta-
tional step away) in Suppl. Table S2. One of the changes on this
list is the methionine to leucine (M to L) change, which is relevant
for drug resistance in HIV. The M46L change in the Protease
gene leads to resistance to certain Protease Inhibitors. A six-patient
dataset from 1997 [20] provides two examples of the fixation of
the M46L change from wildtype (ATG) to resistant (TTG or
CTG). In one of these two patients, we observe a mixture of the
TTG and CTG codons (thus a soft sweep) whereas in the other
patient we only observe the TTG codon (potentially a hard sweep,
see Suppl. Figure S3). Of the other four patients, two did not fix
the M46L mutation and two fixed it at the same time as another
resistance mutation. It is difficult to draw conclusions based solely
on the data from this study because it consists of only 6 patients
[20], but they do provide independent support for our observation
that drug resistance mutations in HIV fix by means of both soft
and hard sweeps.
An interesting question is whether the resistance mutations that
fix stem from standing genetic variation or are due to de novo
mutations during treatment. If the resistance mutations stem from
standing genetic variation, then our estimate of Ne would reflect
the pre-treatment effective population size, whereas, if the muta-
tions would be due to de novo mutation, our estimate would reflect
the effective population size during treatment. We compared the
times of occurrence of soft and hard sweeps relative to the onset of
treatment and found that these were statistically indistinguishable.
There are three possible explanations for this observation. First,
almost all observed sweeps are due to standing genetic variation,
and our estimate of Ne reflects the pre-treatment population. Second,
almostallsweepsaredueto newmutationsand ourestimate reflects
only the on-treatment Ne. Third, sweeps we observe originated
from both standing genetic variation and de novo mutation, but the
start of the treatment had no discernible effect on the effective
population size, and our estimate reflects both the pre-treatment
and on-treatment population size.
We currently have no statistical power to distinguish between
these three possibilities, and so it is possible that, if the second
explanation is true, the pre-treatment population size is much
larger than our estimate. However, some of the sweeps we observed
occurred very early during treatment (within one or two months),
anditseemslikelythat atleasttheseearlysweepsareduetostanding
genetic variation (see also [21]). Note that, counter to intuition,
whether mutations stem from the standing genetic variation or not
does not affect the expected number of origins in a sample (see
Suppl. Figure S4 and [4]).
Our estimate of Ne is similar to earlier estimates that were also
based on resistance mutations [9] and other beneficial mutations
[10]. Our approach may be viewed as a combination of these two
previous approaches. Rouzine and Coffin [10] tested whether a
recombinant or double mutant genotype is present, given that two
beneficial mutations are sweeping through the population at the
same time. Similar to a second mutation that leads to a soft sweep,
a double mutant or recombinant can only occur in a population
with sufficiently high mutational or recombinational input, so that
the frequency of such a genotype in a sample permits the estima-
tion of the mutational or recombinational input. Frost et al [9]
used inferred pre-treatment frequencies of two resistance muta-
tions at the same codon (RT M184I and M184V) to estimate the
effective population size. They found that the two mutations were
present at different pre-treatment frequencies in seven patients. In
a very large population, the frequency of such mutations would be
close to the expected frequency (m=s) in every patient, but in
smaller populations frequencies vary stochastically, and the spread
in the observed frequencies can be used to obtain an upper bound
for the population size.
Our estimate of the supply rate of resistance mutations is much
lower than would be expected if the effective population size were
equal to the number of virus-infected cells in the body, which is
estimated to be 108 [7,8]. At the same time, it is much higher than
estimates of the effective population size based on the level of
diversity at synonymous sites (assuming neutrality of synonymous
variation) which would be around 103 [6]. Next we discuss possible
reasons for these discrepancies.
Why is our estimate higher than Ne from synonymous
diversity?
We propose three possible explanations for the large difference
between our estimate based on the frequency of soft sweeps and
the estimate based on the traditional analyses of synonymous
diversity. All three explanations may be contributing to this differ-
ence. First, some synonymous mutations may be deleterious [22].
Second, positive and negative selection on linked sites (draft and
background selection) reduce diversity at synonymous sites, but
may have a weaker effect on beneficial mutations such as K103N.
Our observation that the fixation of drug resistance mutations is
accompanied by a reduction in diversity provides evidence for
this explanation. Third, synonymous diversity may take a long
time to recover after a sweep or a bottleneck. We discuss the third
option in more detail and provide evidence from the data for this
explanation.
Figure 3. Nucleotide diversity over time in 30 patients.
Nucleotide diversity at synonymous (black) and non-synonymous
(red) sites. The time point ‘‘before fixation’’ is the last sample in each
patient taken before the observed fixation of a resistance mutation. The
time point ‘‘immediately after fixation’’ is the first sample in each
patient in which the drug resistance mutation is observed to be fixed.
The third and the fourth time points denote samples in each patient
taken 1–180 days and 181–700 days after the observed fixation of the
resistance mutation respectively. Dashed horizontal lines show the
nucleotide diversity at synonymous (black) and non-synonymous (red)
sites at the time point ‘‘before fixation’’ to provide a reference for
subsequent time points.
doi:10.1371/journal.pgen.1004000.g003
Selective Sweeps in HIV
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ymous sites steadily recovers after the sweep (Figure 3). However,
even after 6 to 18 months, synonymous diversity remains signifi-
cantly depressed, with a median reduction of {53% (P~0:01)
compared to pre-sweep diversity, up from {66% (P~10{4)
directly after the sweep. In contrast, after 6 to 18 months after the
sweep, non-synonymous diversity is fully recovered, with the
median amount of diversity increased by z5% (n.s.) compared to
pre-sweep, up from {32% (P~0:01) directly after the sweep.
Hence, even relatively infrequent selective sweeps can keep
synonymous diversity at a level much below the equilibrium.
The observation that stronger negative selection leads to faster
recovery is consistent with recent predictions about the approach
of the distribution of allele frequencies to stationarity at a single
locus [23]. This effect is well known in systems biology: stronger
negative feedback leads to a faster the recovery time [24]. A
heuristic analysis (Text S1), similar to analyses in [25–27], shows
that neutral sites recover half of their diversity in roughly Ne
generations while deleterious sites recover half of their diversity in
roughly 1=s generations, where s is the strength of selection against
deleterious mutations. Interestingly, for realistic values of the
mutation rate, the recovery time is independent of the mutation
rate (see Text S1 and Suppl. Figure S5).
The dynamics of how diversity recovers are likely not specific to
HIV but typical to any large population. In humans, for example,
Europeans have reduced synonymous diversity, but a similar amount
of non-synonymous diversity, compared to Africans [28,29]. This is
consistent with the explanation that non-synonymous diversity
has had enough time to recover since the out-of-Africa bottleneck,
but synonymous diversity has not. This observation leads to a
counterintuitivepracticalimplication.Sincenon-synonymousdiver-
sity recovers faster, it is usually closer to its equilibrium than syn-
onymous diversity. Thus non-synonymous sites may in fact be more
useful for classical population genetics inference than synonymous
sites.
Why is our estimate lower than the number of infected
cells?
HIV populations consist of a heterogeneous collection of
genotypes, many of which may carry deleterious and advanta-
geous mutations. A new mutation arises in one such genotype and
is therefore linked, at least temporarily, to other mutations already
present in it. The probability that a new mutation eventually fixes
or goes extinct thus depends not only on its own selective effect but
also on the combined fitness of the genetic background in which it
arose [30,31]. The effects of linkage on the fates of new mutations
are complex and comprise an active area of research [30–39], but
the qualitative picture is straightforward. The fates of neutral, dele-
terious and weakly beneficial mutations are entirely determined by
the background in which they arise [31]: only mutations that arise
on high-fitness genotypes have a chance to persist in the population
(Figure 4a, b). The number of segregating neutral mutations in such
a population will be small because high-fitness individuals comprise
only a small fraction of the population [30,33,34]. At the other
extreme, adaptive mutations with very large selective effects survive
and spread irrespective of the genetic background in which they
arise (Figure 4c). The effective population size for such mutations
may be close to the census population size [13]. The effective
populationsizeformutationswith intermediateeffectsissomewhere
in between (Figure 4d).
The effective size we estimate from the K103N mutation is
several orders of magnitude smaller than the estimated census size.
This could mean that the distribution of fitnesses in the viral
population due to ongoing positive and negative selection is wide,
so that even a highly beneficial mutation such as K103N needs to
appear on a relatively fit genetic background to have a good
chance of survival. The width of the distribution of fitnesses in
within-patient HIV populations is currently unknown. Theory
shows that the width of the fitness distribution depends on the rates
and typical effects of beneficial and deleterious mutations and on
the viral census size [30,39,40], quantities that are difficult to
estimate. Neher and Leitner recently estimated that at least 15% of
non-synonymous mutations have a selection coefficient exceeding
0:8% [41]. In another study, Batorsky et al concluded that the rate
of adaptation of HIV rate is consistent with an exponential
distribution of fitness effects of adaptive mutations with mean
0:5% [42]. If these estimates are accurate, they could imply that
the distributions of fitnesses in within-patient HIV populations are
narrow so that fixation of highly beneficial mutations like K103N
should not be affected by linked selection.
Other effects may help explain why the effective size of HIV is
smaller than the census size. For example, the treatment itself may
reduce the population size of the virus before resistance evolves. If
this is true, then soft sweeps must be especially common in patients
who were treated with inferior drugs in the 1980s and 1990s,
because early treatments were not as successful in reducing the
population size of the virus. If treatment reduces the effective
population size, then this would also mean that soft sweeps should
be more common in patients who fail early versus patients who fail
later (after more time on treatment). We find no evidence for such
an effect in the current data set (results not shown). Alternatively,
Figure 4. Fates of mutations in a heterogeneous population.
This schematic shows the fates (‘‘fix’’, fixation; ‘‘ext’’ extinction) of
mutations with different selective effects, as indicated in each panel,
depending on the fitness of the genotype they occur in. The light gray
area shows the distribution of fitnesses in the population. Small gray
arrows show how natural selection changes the distribution of
genotypes: fitter than average genotypes increase in frequency, less
fit than average genotypes decrease in frequency. Colored arrows show
the effect size of new mutations: neutral mutations (effect size 0) are
shown in blue (panel a.), adaptive mutations (effect size w0) are shown
in orange (panels b. weakly beneficial, panel c. strongly beneficial, panel
d. intermediate beneficial effect). Mutations that are destined for
fixation (extinction) are shown with solid (dashed) arrows. Mutations
with a large beneficial effect can fix if they arise in any background
(panel c), whereas mutations with a small beneficial effect can fix only if
they arise in a very fit background (panels a., b., and d.). The resulting
effective population size for mutations with a given effect size is shown
as red shading.
doi:10.1371/journal.pgen.1004000.g004
Selective Sweeps in HIV
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effective population size for resistance mutations.
We obtained our population size estimate under the assump-
tion—most certainly violated in reality at least to some extent—
that all patients have the same constant effective population size.
Unfortunately, we do not have sufficient statistical power to relax
this assumption. Longitudinal data with denser and deeper
sampling is required to study inter-patient and temporal hetero-
geneity in viral adaptation.
Conclusions
We observe soft and hard sweeps in HIV, which leads to an
estimated effective population size relevant for adaptation of
around 1:5|105. This number is much higher than what the
observed level of synonymous diversity suggests. An important
caveat of our approach is that we assume that the supply rate of
beneficial mutations is similar in all patients, which may not be
true. Larger samples are needed to estimate the patient-specific
supply rate of adaptive mutations. Our results show that neither
synonymous diversity, nor the census population size provide
sufficient information to infer a population’s adaptive potential,
which explains, in part, why it is hard to predict whether and when
adaptive evolution will occur. Our finding that adaptive evolution
in HIV is limited by the supply rate of beneficial mutations suggests
that a relatively modest reduction of the effective population size
may help prevent the evolution of drug resistance, and it is possible
that the reduction of Ne that results from modern combination
therapy, does just that [21]. In addition, if the adaptive potential of
the virus is limited because a large proportion of the beneficial
mutations land on inferior genetic backgrounds, then the use of
mutagenicdrugs,incombinationwith standard antiretroviral drugs,
should reduce the adaptive potential of the virus [43]. Finally, our
results confirm what has already been predicted theoretically, that
the idea of a single effective population that can be used to describe




Out of a larger dataset [12], we used viral sequences from
patients for which we had samples at two consecutive time-points
that satisfy the following two criteria. (1) At the first time-point, no
known resistance mutations to any of the drugs used in the trial
was present at more than 30% frequency in the sample. See below
for the list of drugs and mutations. (2) At the next time-point, at
least one drug resistant allele increases in frequency by at least
70%. There were 30 such patients. In most cases (26 out of 30) the
frequency of the mutations changes from 0 to 100%. The four
exceptions are patient 89 (mutation G190S changed from 0 to
75%), patient 168 (mutation K103N changed from 0 to 83%),
patient 22 (mutation K103N changed from 13% to 100%, while
mutation V82A changed from 0 to 100%), and patient 81
(mutation K103N changed from 14 to 100%). In most cases (24
out of 30) only a single drug-resistance mutation went to fixation (2
mutations in patients 22, 56, 87, 91, 154 and 166). For details per
patient, see supplementary table S1.
The patients were treated with Zidovudine, Lamivudine, Efavirenz
and Indinavir [12]. There are many known mutations that confer
resistance to one or more of these drugs. We are interested in the
fixation of the first resistance mutation in a viral population. We
used the following list of major drug-resistance mutations (the
number is the codon and the letter is the amino-acid that confers
resistance). Protease: 46IL, 82AFT, 84V; Reverse Transcriptase:
41L, 62V, 65R, 67N, 70R, 75I, 77L, 100I, 101P, 103N, 106MA,
108I, 116Y, 151M, 181CI, 184VI, 188LCH, 190SA, 210W,
215YF, 219QE, 225H [45].
Our dataset consists of coding sequences of the regions of the
Pol gene that encode for protease (all 297 basepairs) and reverse
transcriptase (first 689 basepairs). We analyze separately all third
codon position sites and all first and second codon position sites.
Most observed mutations at third codon position sites have no effect
ontheaminoacid,andweexpectthesesynonymousmutationstobe
neutral or nearly neutral. Throughout the paper, we refer to muta-
tions at first and second position sites as non-synonymousand muta-
tions at third position sites as synonymous. Most mutations at the
firstorsecond codonpositionschangethe amino acid,andweexpect
that most such non-synonymous mutations are selected against.
No change in genetic diversity was observed in 27 control inter-
vals that also started with drug susceptible virus but in which no
fixation of drug resistant amino-acids occurred (largest frequency
change of drug resistant amino-acid in these intervals was 30%).
We found no difference in pre-sweep diversity at third codon
position sites between hard sweep and soft sweep patients.
Recombination
To determine whether recombination affects the reduction of
diversity, we split the sequences into a part close to the selected site
(less than 50, 100, or 200 basepairs distance from the selected site)
and the complementary part far from the selected site. We found
no difference in the amount of diversity loss in the close versus far
sites. Earlier work suggests that selection may be so strong, relative
to the recombination rate, that the sweeps can affect the entire
genome [17,41].
Estimating the supply rate of resistance mutations
We can use the counts of the two beneficial alleles (AAT and
AAC at the 103rd amino acid of RT) in the post-sweep samples to
estimate the the supply rate of resistance mutations. We assume
that the mutation rate mAAT to the AAT codon and the mutation
rate mAAC to the AAC codon are equal to each other, mAAT~
mAAC:m.I fNe is the effective population size, then h~2Nem, and
h=2 is the total population-wide beneficial mutation rate, which we
also call ‘‘the supply rate of resistance mutations’’.
Theory predicts that the population frequency x of the AAC
allele follows a beta-distribution with parameters (h=2,h=2) (see
[4]). The number k of AAC alleles in a sample of size n follows the
binomial distribution with parameters n and x. Thus, the likelihood
of observing k1,...,kM AAC alleles in samples of size n1,...,nM in










where B(a,b) is the beta-function. By maximizing expression (1), we
obtain the maximum likelihood estimate ^ h h~0:62. The estimated
supply rate of K103N mutations is ^ h h=2~0:31. The 95% bootstrap
confidence interval for the supply rate obtained by resampling
patients with replacement is ½0:17,0:97 .
We estimate the effective population size as ^ h h=2m. Because we
only consider the K103N mutation, m&2|10{6 [19,46]. Note
that this number is lower than the typical per site mutation rate,
because most (*85%) mutations in HIV are transitions, whereas
the A to C and A to T mutations that create the K103N change,
are both transversions. We thus estimate the effective population
size to be 1:5|105 (95% confidence interval ½0:8|105,4:8|105 ).
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mutations, we can also predict the probability that the beneficial
mutation originates from 1, 2 or more mutational origins following
[4]. For a sample of size 6 (the median in the dataset) and the
estimated supply rate of beneficial mutations of 0:31, the predicted
probability that all observed beneficial alleles in the sample stem
from a single origin is 30%, the probability that they stem from 2
origins is 43%, 3 origins: 22% and 4, 5 or 6 origins: 6%. This
shows that even if the supply rate is exactly the same in all
populations, the observed sweep signature can vary widely.
Supporting Information
Figure S1 Nucleotide diversity reduction due to different
fixations. Nucleotide diversity at all sites. The patients are split
in four groups: the first group in which one codon of the K103N
was fixed (K103N one codon), a group in which a mixture of two
codons of K103N was fixed (K103N two codons), a group in
which a different amino acid change was fixed (Other mutation)
and a group in which two resistance mutations were fixed (Two
mutations). Large red circles show the median for each group. The
shape of the points reflects the treatment the patient was on: circle:
treated with indinavir then later switched to efavirenz combination
therapy, triangle: treated with indinavir + efavirenz, plus-sign:
treated with indinavir, cross: treated with ZDV/3TC + efavirenz
diamond: treated with ZDV/3TC, later switched to efavirenz
combination therapy.
(PDF)
Figure S2 Soft and hard sweep example. A. Soft sweep in
patient 089. Codon GGC coding for glysine at position 190 was
replaced by day 56 by codon AGC coding for serine, which
confers resistance to NNRTI drugs. The G190S mutation appears
to have occurred on at least two different backgrounds. As
predicted by theory [18], the site is embedded in a region of high
linkage disequilibrium. The different haplotypic backgrounds are
indicated by differently colored pastel backgrounds. Genetic
diversity was reduced by 38%. The plot shows the polymorphic
sites in the reverse transcriptase region, excluding all singletons.
Each row represents a sequenced viral isolate. Each column
represents a polymorphic site, with the derived synonymous and
non-synonymous polymorphisms shown in black and orange
respectively. Codons 103, 108, 188, 190 and 225 are all linked to
NNRTI resistance and are shown explicitly. They are grey when
when in the susceptible state and blue when in the resistant state.
Mutations in these codons are colored pink. B. Hard sweep in
patient 159. Codon GGA coding for glysine at position 190 was
replaced by day 225 by codon GCA coding for alanine, which
confers resistance to NNRTI drugs. The G190A mutation appears
tohave occurredonatleasta single haplotypicbackground.Genetic
diversity was reduced by 67%. The plot shows the polymorphic sites
in the reverse transcriptase region, excluding all singletons. Each
row represents a sequenced viral isolate. Each column represents a
polymorphic site, with the derived synonymous and non-synony-
mous polymorphisms shown in black and orange respectively.
Codons 190 is shown explicitly. It is colored grey when when in the
susceptible state and blue when in the resistant state. Mutations in
this codon are colored pink.
(PDF)
Figure S3 Soft and hard sweep example. A. Soft sweep in
patient 6 [20] Codon ATG coding for methionine at position 46
was replaced in 1993/10 by codons CTG and TTG, both coding
for leucine, which confers resistance to Protease inhibitor drugs.
The plot shows the polymorphic sites in the protease region,
excluding all singletons. Each row represents a sequenced viral
isolate. Each column represents a polymorphic site, with the
derived synonymous and non-synonymous polymorphisms shown
in black and orange respectively. Codons 10, 46, 71 are linked to
Protease Inhibitor drug resistance and shown explicitly. They are
colored grey when when in the susceptible state and blue when in
the resistant state. Mutations in these codons are colored pink. The
viral load in this patient was around 106 before treatment, it went
down approximately 1:5 log values and rebounded quickly to its
original level (see figure 1 in [20]). B. Hard sweep in patient 3 [20]
Codon ATG coding for methionine at position 46 was replaced in
1994/02 by codon TTG, which codes for leucine, which confers
resistance to Protease inhibitor drugs. The plot shows the
polymorphic sites in the protease region, excluding all singletons.
Each row represents a sequenced viral isolate. Each column
represents a polymorphic site, with the derived synonymous and
non-synonymous polymorphisms shown in black and orange
respectively. Codons 10, 46, 71 are linked to Protease Inhibitor
drug resistance and shown explicitly. They are colored grey when
when in the susceptible state and blue when in the resistant state.
Mutations in these codons are colored pink. The viral load in this
patient was slightly higher than 105, it went down to below the
detection limit of 104 and stayed low for more than six months,
after which it rebounded (see figure 1 in [20]).
(PDF)
Figure S4 Probability of a single origin (hard sweep) in a sample
of size 6. Simulation results show that the number of origins is
independent of whether or not standing genetic variation is
involved, and if standing genetic variation is involved, the number
of origins is independent of the selection coefficient of the allele
before or after the start of treatment. The horizontal line denotes
the theoretical expectation [4]. The bars denote the probability
that a sample of size six consists of just one origin, averaged over
1000 runs. The population size in the simulations is 150,000 and
the mutation rate 2|10{6, so that h=2~0:3.
(PDF)
Figure S5 Predicted response time. Comparison of the response
time thalf, defined as the time it takes for H to recover 50% of its
loss of diversity, from the heuristic model and from simulations.
Dashed lines show thalf~s{1 log(2) (for sw0)o rthalf~N log(2)
(for s~0). Dots display averages over 1000 simulations of a
haploid Wright-Fisher population with N~104 individuals for
each pair of values of u and s. In all cases, v~u.
(PDF)
Table S1 Patient details. For each of the (a.) 30 patients that
were included in the analysis, this table gives (b.) the codon(s) of
the resistance mutation(s) that occurred (with nucleotide changes
indicated for all mutations except the 103rd codon of RT, P82
indicates the 82nd codon in Protease, all other codons are in RT),
(c.) the level of diversity before and (d.) after the sweep, (e.) the
sample size of the first sample after the sweep, (f.) the number of
AAC and (g.) AAT alleles observed in the first sample after the
sweep, and (h.) the treatment the patient was receiving.
(PDF)
Table S2 List of amino acid changes that can be achieved by
two or more single nucleotide changes and thus allow the obser-
vation of soft sweeps at the beneficial site itself. In almost all cases,
the relevant mutations are transversions (TV). In the last three
cases (marked with an asterisk), one of the mutations is a transition
(TS). In these cases, the difference in mutation rates (higher for
transitions) will make it less likely to observe a soft sweep.
(PDF)
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